Although development of a jab for the H5N1 strain of avian flu is well under way, other strains are receiving less attention ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

Chronic chikungunya arthritis often mimics rheumatoid arthritis, complicating diagnosis and therapy, and necessitating ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

Secondary offerings from biotechs Immunovant, Kymera Therapeutics, and Wave Life Sciences prompted some huge insider buying ...

US regulators have approved GSK’s Exdensur treatment for severe asthma with an eosinophilic phenotype, marking the first ...

GSK’s Exdensur is approved by the US FDA as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and ...

A study published in Neurology looks at the association between high fat cheese and dementia risk. Dr Richard Oakley, Associate Director of Research and Innovation at Alzheimer’s Society, said: ...

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has announced the purchase of 230,000 of its own ordinary shares as part of its ongoing ...

Aurinia Pharmaceuticals posts record Lupkynis sales, addresses FDA queries with new data, and faces new competition from ...

The boss of Britain’s largest drug developer has praised the US as the best place to invest amid fears over the waning appeal ...

As of Tuesday, December 16, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 8.47%, which has investors ...